Isaac Francis

Arrowhead Pharmaceuticals (NASDAQ:ARWR) today announced that the Chinese National Medical Products Administration (NMPA) has approved REDEMPLO® (plozasiran) for the reduction of triglyceride levels in adult patients with familial chylomicronemia syndrome (FCS).

Compass Pathways (NASDAQ:CMPS) reached a pivotal milestone on Wednesday, January 7, 2026, as the U.S. FDA accepted the company’s Investigational New Drug (IND) application for COMP360, its proprietary synthetic psilocybin treatment, for the treatment of Post-Traumatic Stress Disorder (PTSD).

Infosys (NYSE:INFY) and Cognition announced a strategic collaboration on January 7, 2026, to scale Devin, the world’s first autonomous AI software engineer, across Infosys’ vast global operations.

Ionis Pharmaceuticals (NASDAQ:IONS) shares hovered near 52-week highs Wednesday after partner GSK (NYSE:GSK) announced that its experimental drug, bepirovirsen, successfully met the primary endpoints in two pivotal Phase 3 trials, B-Well 1 and B-Well 2.

A generational wealth shift could drive wider crypto adoption as younger, tech-savvy investors gain control of assets.

A Coinbase analyst says quantum computing risks to bitcoin may extend beyond wallets to its core security and mining model.

Polymarket quietly rolled out taker fees on short-term crypto markets to support liquidity incentives.

US community banks want lawmakers to close a GENIUS Act loophole they say allows stablecoins to undercut lenders.

Flow has outlined how a protocol flaw led to a $3.9m exploit and what steps were taken to secure the network.

Israel deepens ties with Somaliland as its foreign minister makes a historic visit following recognition.